Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAMANT
2015-000630-30Phase 2Completed
- Sponsor
- Axon Neuroscience
- Start
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of AADvac1 in Alzheimer's disease (AD), sponsored by Axon Neuroscience. Primary endpoint: Safety and tolerability. Started Oct 2015; status: completed.
02
Drugs
AADvac1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-000630-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000630-30.